Estrogen receptor expressing breast cancers (BC) are classically treated with endocrine therapy. Prolonged endocrine therapy often results in a metastatic disease (MBC), for which a standardized eective therapy is still lacking. Thus, new drugs are required for primary and metastatic BC treatment. Here, we report that the Food and Drug Administration (FDA)-approved drugs, ouabain and digoxin, induce ER degradation and prevent proliferation in cells modeling primary and metastatic BC. Ouabain and digoxin activate the cellular proteasome, instigating ER degradation, which causes the inhibition of 17-estradiol signaling, induces the cell cycle blockade in the G2 phase, and triggers apoptosis. Remarkably, these eects are independent of the inhibition of the Na/K pump. The antiproliferative eects of ouabain and digoxin occur also in diverse cancer models (i.e., tumor spheroids and xenografts). Additionally, gene profiling analysis reveals that these drugs downregulate the expression of genes related to endocrine therapy resistance. Therefore, ouabain and digoxin behave as ‘anti-estrogen’-like drugs, and are appealing candidates for the treatment of primary and metastatic BCs.

Busonero, C., Leone, S., Bianchi, F., Maspero, E., Fiocchetti, M., Palumbo, O., et al. (2020). Ouabain and Digoxin Activate the Proteasome and the Degradation of the ERalpha in Cells Modeling Primary and Metastatic Breast Cancer. CANCERS [10.3390/cancers12123840].

Ouabain and Digoxin Activate the Proteasome and the Degradation of the ERalpha in Cells Modeling Primary and Metastatic Breast Cancer

Claudia Busonero
Methodology
;
Stefano Leone
Methodology
;
Marco Fiocchetti
Methodology
;
Manuela Cipolletti
Methodology
;
Stefania Bartoloni
Methodology
;
Filippo Acconcia
Writing – Review & Editing
2020

Abstract

Estrogen receptor expressing breast cancers (BC) are classically treated with endocrine therapy. Prolonged endocrine therapy often results in a metastatic disease (MBC), for which a standardized eective therapy is still lacking. Thus, new drugs are required for primary and metastatic BC treatment. Here, we report that the Food and Drug Administration (FDA)-approved drugs, ouabain and digoxin, induce ER degradation and prevent proliferation in cells modeling primary and metastatic BC. Ouabain and digoxin activate the cellular proteasome, instigating ER degradation, which causes the inhibition of 17-estradiol signaling, induces the cell cycle blockade in the G2 phase, and triggers apoptosis. Remarkably, these eects are independent of the inhibition of the Na/K pump. The antiproliferative eects of ouabain and digoxin occur also in diverse cancer models (i.e., tumor spheroids and xenografts). Additionally, gene profiling analysis reveals that these drugs downregulate the expression of genes related to endocrine therapy resistance. Therefore, ouabain and digoxin behave as ‘anti-estrogen’-like drugs, and are appealing candidates for the treatment of primary and metastatic BCs.
Busonero, C., Leone, S., Bianchi, F., Maspero, E., Fiocchetti, M., Palumbo, O., et al. (2020). Ouabain and Digoxin Activate the Proteasome and the Degradation of the ERalpha in Cells Modeling Primary and Metastatic Breast Cancer. CANCERS [10.3390/cancers12123840].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11590/375809
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 6
social impact